GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Apures Co Ltd (XKRX:149300) » Definitions » Revenue per Share

Apures Co (XKRX:149300) Revenue per Share : ₩16.91 (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Apures Co Revenue per Share?

Apures Co's revenue per share for the six months ended in Dec. 2023 was ₩16.91. Apures Co's revenue per share for the trailing twelve months (TTM) ended in Dec. 2023 was ₩16.91.

Warning Sign:

Apures Co Ltd revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue Per Share Growth Rate of Apures Co was -21.70% per year. During the past 3 years, the average Revenue Per Share Growth Rate was 7.80% per year. During the past 5 years, the average Revenue Per Share Growth Rate was 0.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Apures Co's Revenue per Share or its related term are showing as below:

XKRX:149300' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -32.9   Med: -1.3   Max: 8.8
Current: 7.8

During the past 10 years, Apures Co's highest 3-Year average Revenue Per Share Growth Rate was 8.80% per year. The lowest was -32.90% per year. And the median was -1.30% per year.

XKRX:149300's 3-Year Revenue Growth Rate is ranked better than
54.23% of 201 companies
in the Medical Diagnostics & Research industry
Industry Median: 6 vs XKRX:149300: 7.80

Apures Co Revenue per Share Historical Data

The historical data trend for Apures Co's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apures Co Revenue per Share Chart

Apures Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.58 13.49 26.17 21.60 16.91

Apures Co Semi-Annual Data
Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.58 13.49 26.17 21.60 16.91

Competitive Comparison of Apures Co's Revenue per Share

For the Diagnostics & Research subindustry, Apures Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apures Co's PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Apures Co's PS Ratio distribution charts can be found below:

* The bar in red indicates where Apures Co's PS Ratio falls into.



Apures Co Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Apures Co's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Revenue Per Share (A: Dec. 2023 )=Revenue (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=658.916/38.973
=16.91

Apures Co's Revenue Per Share for the quarter that ended in Dec. 2023 is calculated as

Revenue Per Share (Q: Dec. 2023 )=Revenue (Q: Dec. 2023 )/Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
=658.916/38.973
=16.91

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was ₩16.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apures Co  (XKRX:149300) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Apures Co Revenue per Share Related Terms

Thank you for viewing the detailed overview of Apures Co's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Apures Co (XKRX:149300) Business Description

Traded in Other Exchanges
N/A
Address
44, Hansan-gil, Cheongbuk-eup, Gyeonggi-do, Pyeongtaek-si, KOR, 17792
Apures Co Ltd is a South Korea based company engaged in the development of transgenic animals to support bio heterogeneous long-term commercialization and new drug efficacy research. It has focused its research capabilities on developing transgenic mini pigs based on gene editing technology and somatic cell nuclear transfer technology.

Apures Co (XKRX:149300) Headlines

No Headlines